Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06961084 · ClinicalTrials.gov registry record · Phase 2
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
A Phase 2 study of Thyroid Cancer, sponsored by Thomas Hope.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT06961084: Recruiting Phase 2 study of Thyroid Cancer, sponsored by Thomas Hope.
NCT06961084 is a Phase 2 study of Thyroid Cancer that is actively recruiting participants, run by Thomas Hope. The registered enrollment target is 62 participants, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06961084, a Phase 2 study of Thyroid Cancer, is actively recruiting participants, sponsored by Thomas Hope.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
Persons diagnosed with thyroid cancer are often treated initially with a thyroidectomy, which is followed by ablation using Iodine-131, a therapy which has been shown to be effective and safe. Imaging of metastatic thyroid cancer has been performed with whole body I-131 and Iodine 123 (I-123) imaging for many decades and use I-123 for staging studies. Iodine 124 (I-124) is a radioisotope of iodine which emits a positron and is imaged using PET (positron emission tomography). This is a single arm prospective trial that evaluates the ability of Iodine-124 (I-124) to detect metastatic thyroid cancer compared to non-interventional, usual care I-123 and I-131 images.
Primary Outcome
Participant-level agreement between I-124 PET and the combination of I-123/I-131 SPECT will be measured. A participant will be classified as showing agreement only if all six regions demonstrate agreement; disagreement in one or more regions will result in a classification of disagreement. Positive percent agreement (PPA) and negative percent agreement (NPA) will be reported with corresponding 95% confidence intervals.
Conditions Studied
Interventions
- DRUG Iodine-124
- PROCEDURE Positron Emission Tomography (PET)/Computerized tomography (CT)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2025-07-14 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 2 |
What NCT06961084 shows while recruiting
NCT06961084 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 62 participants, a relatively small participant target, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 2 interventions - of which Iodine-124 is the first listed.
NCT06961084 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06961084 about?
NCT06961084 is a clinical study titled "Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer". Persons diagnosed with thyroid cancer are often treated initially with a thyroidectomy, which is followed by ablation using Iodine-131, a therapy which has been shown to be effective and safe. Imaging of metastatic thyroid cancer has been performed with whole body I-131 and Iodine 123 (I-123) imagin...
What is the current status of trial NCT06961084?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2025-07-14. Estimated completion is 2026-03-31.
What conditions does trial NCT06961084 study?
This clinical trial studies the following conditions: Thyroid Cancer.
What interventions are being tested in trial NCT06961084?
The interventions under investigation include: Iodine-124 (DRUG), Positron Emission Tomography (PET)/Computerized tomography (CT) (PROCEDURE).
Who is sponsoring clinical trial NCT06961084?
This trial is sponsored by Thomas Hope, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06961084 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06961084's enrollment target sits among peer trials
62 23rd of 46 higher than 24 of 46 other Thyroid Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
RECRUITING · Phase 2
-
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
RECRUITING · Phase 2
-
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
RECRUITING · Phase 2
-
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
RECRUITING · Phase 2
-
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03231150 · 62 participants · NA
Plantar Fasciitis Randomized Clinical Control Trial
- NCT03458676 · 62 participants · NA
Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies
- NCT03596086 · 62 participants · Phase 1
HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
- NCT03603405 · 62 participants · Phase 1
HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI